• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

VA Awards HistoSonics with $90M Contract for Tumor Destroying Histotripsy Systems

by Syed Hamza Sohail 11/08/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– HistoSonics , the developer and manufacturer of the Edison Histotripsy System, announced today they have been awarded an exclusive contract to provide Veteran’s Affairs hospitals across the United States access to their novel non-invasive tumor liquefying platforms. 

– The contract, the work of the Veterans Health Administration (VHA) and the Strategic Acquisition Center (SAC) , establishes a $90 million ongoing schedule to develop histotripsy programs at key VA Hospitals. The announced VA contract is the culmination of a multi-year effort by HistoSonics, the company called Project Hero, to ensure meaningful value for Veterans and their families, VHA clinicians, administrators, and caregivers.

HistoSonics Advances Non-Invasive Tumor Treatment with FDA-Cleared Edison Histotripsy System

HistoSonics, a privately held medical device company, is pioneering non-invasive tumor treatment through its proprietary histotripsy technology—a focused ultrasound approach that mechanically destroys and liquefies targeted tissue. The company’s Edison Histotripsy System, now FDA “De Novo” cleared as of October 2023, is aimed at non-invasively treating liver tumors and is being integrated into major U.S. academic centers, community hospitals, and federal healthcare systems in partnership with FIDELIS Sustainability as an exclusive SDVOSB distributor to the Department of Defense and Veterans Affairs medical centers.

Technology Overview

   Histotripsy represents a breakthrough in ultrasound therapy by delivering high-amplitude, ultra-short pulses that generate a “bubble cloud” to destroy and liquefy tumor tissue. This process, which occurs within microseconds, generates powerful mechanical forces that selectively break down cells without using heat, offering a non-thermal and non-invasive alternative to traditional surgery or radiation. HistoSonics’ system is typically performed in a single outpatient session, reducing risks such as infection and toxicity often associated with invasive treatments and enabling rapid recovery and resorption at the treatment site.

System Expansion and Future Applications

   HistoSonics is actively commercializing the Edison Histotripsy System in the U.S. and the HistoSonics Histotripsy System in select global markets, focusing on liver treatments with plans to expand into additional organs like the kidney and pancreas. Headquartered in Ann Arbor, Michigan, with an office in Minneapolis, MN, the company’s approach is to extend the platform’s potential across a broad range of tumor types and clinical applications.

FDA Approval and Use Guidelines

   The Edison System is authorized for the mechanical destruction of liver tumors, targeting partial or complete ablation of tumors that are otherwise unresectable. The FDA has not evaluated this system for specific cancer outcomes (such as local tumor progression or survival rates), and its use is restricted to trained physicians with HistoSonics certification. Comprehensive warnings, precautions, and trial data are included in the device’s Instructions for Use.

Through its innovative approach to focused ultrasound therapy, HistoSonics is transforming the landscape of tumor treatment, offering a promising non-invasive option for patients with liver tumors and charting a path for future histotripsy applications.

“We are pleased that Veterans suffering with tumors will soon have access to this innovative, non-invasive treatment at select VA facilities with interdisciplinary expertise,” said Patrick Malloy MD, Executive Director of the VHA National Radiology Program. Mark Wilson, MD, VHA National Director of Surgery, added, “Histotripsy is an innovative tool that will further enable VA specialists to continue to provide a full continuum of care to Veterans.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |